# Study to Evaluate Safety, Tolerability and PK of C-10355 and C-10358 in Healthy Subjects

> **NCT02392702** · PHASE1 · COMPLETED · sponsor: **Concert Pharmaceuticals** · enrollment: 15 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** C-10355
- **DRUG:** C-10358
- **DRUG:** Kalydeco

## Key facts

- **NCT ID:** NCT02392702
- **Lead sponsor:** Concert Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-06
- **Final completion:** 2015-09
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2015-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02392702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02392702, "Study to Evaluate Safety, Tolerability and PK of C-10355 and C-10358 in Healthy Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02392702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*